NextPharma completes purchase of Lonza lipid oral dosage form manufacturing sites
The Edinburgh site
Ploermel and Edinburgh facilities employ around 390 permanent staff and will allow UK CDMO to expand its technology offering
UK-based CDMO NextPharma has completed its acquisition of two Lonza manufacturing sites for lipid oral dose drugs as liquid-filled hard capsules and softgels, the two companies said Thursday.
The companies had announced the agreement for the sales of the Ploermel (France) and Edinburgh (UK) facilities back in January. The two sites employ around 260 and 130 permanent staff respectively, produce liquid-filled hard capsules (including Licaps) and softgels (including for high potent and hormonal products) for the pharmaceutical and consumer health and nutrition markets.
The purchase will allow NextPharma – which currently specializes in oral and topical (including sterile ophthalmic) finished dosage forms – to develop and broaden its technology offering into lipid-based finished dosage forms on top of high potency capabilities and new chemical entity development services.
Meanwhile, Swiss CDMO Lonza is exiting both softgels and liquid-filled hard capsules for the pharma market, aside from retaining capability for feasibility studies as part of a technology selection offering.
“The strategic divestment of our Ploermel and Edinburgh sites will enable NextPharma to benefit from operational synergies and optimize existing expertise and technologies,” said Gordon Bates, Lonza’s President and Head of Small Molecules.
NextPharma currently has five sites in Germany, one in France and one in Finland, as well as healthcare logistics services in the DACH region.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.